Kymera Therapeutics (KYMR) COO sells 115,977 shares after option exercise

Rhea-AI Filing Summary

Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a series of option exercises and share sales in Kymera Therapeutics, Inc. common stock. He exercised stock options to acquire 109,127 shares at an exercise price of $29.64 per share and then sold 115,977 shares of common stock in multiple open-market transactions at weighted average prices ranging from the mid-$70s to about $80 per share, as detailed in the footnotes. Following these transactions, he directly held 61,202 shares of Kymera common stock. The filing states that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 115,977 shares ($9,048,290)

Net Sell 10 txns

Insider Chadwick Jeremy G

Role Chief Operating Officer

Sold 115,977 shs ($9.05M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	24,727	$0.00	--
Exercise	Common Stock	24,727	$29.64	$733K
Sale	Common Stock	24,727	$80.2586	$1.98M
Exercise	Stock Option (Right to Buy)	84,400	$0.00	--
Exercise	Common Stock	84,400	$29.64	$2.50M
Sale	Common Stock	22,756	$76.7329	$1.75M
Sale	Common Stock	52,975	$77.2059	$4.09M
Sale	Common Stock	8,214	$78.3967	$644K
Sale	Common Stock	6,105	$79.8704	$488K
Sale	Common Stock	1,200	$80.05	$96K

Holdings After Transaction: Stock Option (Right to Buy) — 90,873 shares (Direct); Common Stock — 85,929 shares (Direct)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.96 to $76,94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.95 to $77.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.98 to $78.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.01 to $80.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chadwick Jeremy G

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		M(1)		84,400	A	$29.64	152,452	D
Common Stock	03/23/2026		S(1)		22,756	D	$76.7329(2)	129,696	D
Common Stock	03/23/2026		S(1)		52,975	D	$77.2059(3)	76,721	D
Common Stock	03/23/2026		S(1)		8,214	D	$78.3967(4)	68,507	D
Common Stock	03/23/2026		S(1)		6,105	D	$79.8704(5)	62,402	D
Common Stock	03/23/2026		S(1)		1,200	D	$80.05	61,202	D
Common Stock	03/25/2026		M(1)		24,727	A	$29.64	85,929	D
Common Stock	03/25/2026		S(1)		24,727	D	$80.2586(6)	61,202	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$29.64	03/23/2026		M(1)			84,400	(7)	05/22/2033	Common Stock	84,400	$0	115,600	D
Stock Option (Right to Buy)	$29.64	03/25/2026		M(1)			24,727	(7)	05/22/2033	Common Stock	24,727	$0	90,873	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.96 to $76,94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.95 to $77.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.98 to $78.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.01 to $80.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kymera Therapeutics (KYMR) COO Jeremy G. Chadwick report in this Form 4?

He reported exercising stock options to acquire 109,127 Kymera shares at $29.64 and selling 115,977 shares in open-market trades. After these transactions, he directly held 61,202 shares of Kymera common stock.

How many Kymera Therapeutics (KYMR) shares did the COO sell and at what prices?

He sold 115,977 Kymera common shares in multiple open-market transactions. The filing reports weighted average sale prices with ranges spanning from $75.96 up to $80.86 per share, detailed across several footnotes.

Were the Kymera Therapeutics (KYMR) COO’s trades made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan dated December 10, 2025. Such plans schedule trades in advance, reducing the significance of short-term market timing by the insider.

How many Kymera Therapeutics (KYMR) shares does the COO hold after these transactions?

After the reported option exercises and sales, Jeremy G. Chadwick directly owned 61,202 shares of Kymera common stock. This share count reflects his position immediately following the last transaction disclosed in the Form 4.

What type of securities did the Kymera Therapeutics (KYMR) COO exercise in this Form 4?

He exercised stock options, described as “Stock Option (Right to Buy),” converting derivative rights into 109,127 shares of Kymera common stock at an exercise price of $29.64 per share before selling a portion of those shares.

What vesting information is disclosed about the Kymera Therapeutics (KYMR) stock options?

A footnote explains that 25% of the shares underlying the stock option vested on May 22, 2024, with the remaining shares vesting in equal monthly installments over 36 months, contingent on the COO’s continued employment through each vesting date.